Approval – Page 18 – pharmaceutical daily

March 14, 2019 Off

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

By BusinessWire

– “When-issued” trading of CYCN expected to begin on Nasdaq on March
18, 2019 –

– Separation completion expected April 1, 2019 –

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood
Pharmaceuticals, Inc. (Nasdaq: IRWD…

March 14, 2019 Off

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

By BusinessWire

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that on March 12, 2019 the Compensation Committee of Puma’s
Board of Directors approved the grant of inducement restricted stock…

March 14, 2019 Off

Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

By BusinessWire

CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical
company leveraging its novel technology platforms to develop and
commercialize ready-to-use injectable and infusible drug formulations,
…

March 14, 2019 Off

Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review

By BusinessWire

Anticipated 2019 Events include Enrollment in the Planned SPR994
Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206
Phase 1 Clinical Trials in 2H19

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Spero Therapeutics, …

March 14, 2019 Off

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook

By BusinessWire

NEWTOWN, Pa.–(BUSINESS WIRE)–Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or
the “Company”), a neurotech company focused on neurological wellness,
today reported financial results for the fourth quarter and full y…

March 14, 2019 Off

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results

By BusinessWire

– Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in
Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in
Mid-2019 –

– INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line
…

March 14, 2019 Off

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results

By BusinessWire

FREMONT, Calif.–(BUSINESS WIRE)–Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced financial results for the
fourth quarter and year ended December 31, 2018, as well as recent
bus…

March 14, 2019 Off

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

By BusinessWire

Lead Tri-specific T cell Activating Construct (TriTAC) candidate,
HPN424, continues to advance in a Phase 1 clinical trial for the
treatment of prostate cancer

Initial public offering, successfull…

March 14, 2019 Off

BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

By BusinessWire

Completed Acquisition of Asterias Biotherapeutics, Inc.

Completed Distribution of AgeX Therapeutics Shares to BioTime
Shareholders

Entered Into Exclusive Collaboration with Orbit Biom…

March 14, 2019 Off

Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Achievements and Key 2019 Milestones

By BusinessWire

Conference Call Today at 4:30 p.m. Eastern Time

WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24TTPH&src=ctag" target="_blank"gt;$TTPHlt;/agt; lt;a href="https://twitter.com/hasht…